Bank of New York Mellon
KNTE

Bank of New York Mellon’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Bank of New York Mellon’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-97,814
Closed -$611K – 4483
2023
Q1 		$611K Sell
97,814
-1,197
-1% -$7.29K ﹤0.01% 3384
2022
Q4 		$604K Buy
99,011
+1,690
+2% +$13.8K ﹤0.01% 3458
2022
Q3 		$1.16M Buy
97,321
+8,792
+10% +$115K ﹤0.01% 3129
2022
Q2 		$1.12M Sell
88,529
-4,492
-5% -$41.8K ﹤0.01% 3163
2022
Q1 		$1.05M Sell
93,021
-1,317
-1% -$14.5K ﹤0.01% 3283
2021
Q4 		$1.67M Buy
94,338
+27,348
+41% +$577K ﹤0.01% 3098
2021
Q3 		$1.54M Buy
66,990
+26,267
+65% +$572K ﹤0.01% 3151
2021
Q2 		$948K Buy
40,723
+4,957
+14% +$126K ﹤0.01% 3450
2021
Q1 		$1.11M Buy
+35,766
New +$1.25M ﹤0.01% 3269

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon's KNTE Position: Q2 2023 in Review

Bank of New York Mellon sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2023, closing a stake of 97,814 shares — an estimated $611K sold.

Bank of New York Mellon first reported a position in KNTE in Q1 2021 and held it in 9 quarters. The position peaked at $1.67M in Q4 2021. 72 funds tracked by Wall St. Rank hold KNTE as of Q2 2023.

  • Bank of New York Mellon reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 97,814 Kinnate Biopharma Inc. Common Stock shares in Q2 2023, an estimated $611K.
  • Bank of New York Mellon first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Bank of New York Mellon's Kinnate Biopharma Inc. Common Stock position peaked at $1.67M in Q4 2021.
  • 72 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.